2026-03-30 11:06:43
PDS Biotechnology Corp Reports Year-End 2025 Financial Results and Updates on Clinical Programs
Expected Stock impact: Slightly Positive
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its financial results for the year ended December 31, 2025, revealing a net loss of approximately $34.5 million, or $0.74 per share, compared to a net loss of $37.6 million, or $1.03 per share for the previous year. The company highlighted significant progress in its clinical programs, particularly the VERSATILE-003 Phase 3 trial for PDS0101, which has been amended to incorporate progression-free survival (PFS) as an interim primary endpoint. This change is expected to shorten the trial duration and reduce costs, potentially accelerating the path to regulatory submission. Additionally, PDS Biotechnology reported a decrease in research and development expenses to $19.0 million from $22.6 million in 2024, attributed to lower manufacturing and personnel costs. The company also presented early results from its PDS01ADC Phase 2 program, demonstrating promising outcomes in patients with metastatic castration-resistant prostate cancer. The financial results and clinical updates were shared during a conference call held on March 30, 2026, where CEO Frank Bedu-Addo emphasized the company's commitment to advancing its innovative therapies efficiently. With a cash balance of $26.7 million as of December 31, 2025, PDS Biotechnology is well-positioned to continue its clinical development efforts and explore further opportunities in the immunotherapy space.
